Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction
| Autor: | Ola Kleveland, Bjørn Bendz, Pål Aukrust, Kaspar Broch, Jan Kristian Damås, Thor Ueland, Annika E. Michelsen, Ragnhild Helseth, Ingebjørg Seljeflot, Rune Wiseth, Lars Gullestad |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male 0301 basic medicine musculoskeletal diseases medicine.medical_specialty Adolescent Side effect Coronary Artery Disease 030204 cardiovascular system & hematology Antibodies Monoclonal Humanized Placebo Gastroenterology Histones Coronary artery disease Young Adult 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Tocilizumab Double-Blind Method Troponin T Internal medicine medicine Humans ST segment Diseases of the circulatory (Cardiovascular) system Myocardial infarction Non-ST Elevated Myocardial Infarction skin and connective tissue diseases Aged Aged 80 and over Dose-Response Relationship Drug business.industry Neutrophil extracellular traps Middle Aged medicine.disease myocardial infarction 030104 developmental biology chemistry inflammation RC666-701 Female Cardiology and Cardiovascular Medicine business Biomarkers |
| Zdroj: | Open Heart, Vol 8, Iss 1 (2021) Open heart Open Heart |
| ISSN: | 2053-3624 |
| Popis: | ObjectiveBeyond reducing inflammation and troponin T (TnT) release, the interleukin-6 receptor antagonist tocilizumab reduces neutrophil counts in patients with non-ST segment elevation myocardial infarction (NSTEMI). It is unclear if this is related to formation of neutrophil extracellular traps (NETs), carrying inflammatory and thrombotic properties.MethodsIn a placebo-controlled trial, 117 patients with NSTEMI were randomised to a single dose of tocilizumab (n=58) or placebo (n=59) before coronary angiography. The NETs related markers double-stranded DNA (dsDNA), myloperoxidase–DNA (MPO–DNA) and citrullinated histone 3 (H3Cit) were measured at five consecutive time points during hospitalisation (days 1–3).ResultsOur major findings were: (1) H3Cit levels were significantly higher in the tocilizumab compared with the placebo group at all time points (all pConclusionsIn patients with NSTEMI, treatment with tocilizumab is associated with increased circulating H3Cit levels, suggesting that tocilizumab enhances NETosis. Further studies should clarify whether NETosis is a relevant side effect of tocilizumab. Regardless of tocilizumab, dsDNA associated with TnT release, indicating a link between extracellular nuclear material and myocardial injury. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|